The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Karyopharm Therapeutics's share price is $1.06.
Karyopharm Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.28. Hence, Karyopharm Therapeutics's PS Ratio for today is 0.83.
The historical rank and industry rank for Karyopharm Therapeutics's PS Ratio or its related term are showing as below:
KPTI'
s PS Ratio Range Over the Past 10 Years
Min: 0.52 Med: 30.83 Max: 16895
Current: 0.81
During the past 13 years, Karyopharm Therapeutics's highest PS Ratio was 16895.00. The lowest was 0.52. And the median was 30.83.
KPTI's PS Ratio is ranked better than 93.55% of 992
companies
in the Biotechnology industry
Industry Median: 8.85
vs KPTI: 0.81
Karyopharm Therapeutics Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Karyopharm Therapeutics was -33.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -5.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 26.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 89.30% per year.
During the past 13 years, Karyopharm Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 448.50% per year. The lowest was -60.30% per year. And the median was 56.85% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Karyopharm Therapeutics's PS Ratio
For the Biotechnology subindustry, Karyopharm Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Karyopharm Therapeutics's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Karyopharm Therapeutics's PS Ratio falls into.
Karyopharm Therapeutics PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Karyopharm Therapeutics's Share Price of today is $1.06. Karyopharm Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.28.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Karyopharm Therapeutics (NAS:KPTI) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Karyopharm Therapeutics PS Ratio Related Terms
Thank you for viewing the detailed overview of Karyopharm Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Karyopharm Therapeutics (Karyopharm Therapeutics) Business Description
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KPTI has been successfully added to your 